M
Michael Dechant
Researcher at University of Kiel
Publications - 42
Citations - 2762
Michael Dechant is an academic researcher from University of Kiel. The author has contributed to research in topics: Antibody & Antibody-dependent cell-mediated cytotoxicity. The author has an hindex of 25, co-authored 42 publications receiving 2590 citations. Previous affiliations of Michael Dechant include University of Erlangen-Nuremberg.
Papers
More filters
Journal ArticleDOI
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
Jessica L. Teeling,Ruth R. French,Mark S. Cragg,Jeroen van den Brakel,Marielle Pluyter,Haichun Huang,Claude H.T. Chan,Paul W. H. I. Parren,C. Erik Hack,Michael Dechant,Thomas Valerius,Jan G. J. van de Winkel,Martin J. Glennie +12 more
TL;DR: With increasing evidence that mAb therapeutic activity in vivo depends on complement activation, these new CD20 reagents with their slow off-rates and increased potency in CDC hold considerable promise for improved clinical activity.
Journal ArticleDOI
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells.
Matthias Peipp,Jeroen J. Lammerts van Bueren,Tanja Schneider-Merck,Wim K. Bleeker,Michael Dechant,Thomas Beyer,Roland Repp,Patrick Van Berkel,Tom Vink,Jan G. J. van de Winkel,Jan G. J. van de Winkel,Paul W. H. I. Parren,Thomas Valerius +12 more
TL;DR: It is demonstrated for the first time that lack of fucose does not generally increase the ADCC activity of therapeutic antibodies and that the impact of Fc glycosylation on ADCC is critically dependent on the recruited effector cell type.
Journal ArticleDOI
Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage
Tanja Schneider-Merck,Jeroen J. Lammerts van Bueren,Sven Berger,Kai Rossen,Patrick Van Berkel,Stefanie Derer,Thomas Beyer,Stefan Lohse,Wim K. Bleeker,Matthias Peipp,Paul W. H. I. Parren,Jan G. J. van de Winkel,Jan G. J. van de Winkel,Thomas Valerius,Michael Dechant +14 more
TL;DR: The results identify myeloid cell-mediated ADCC as a potent and additional mechanism of action for EGF-R–directed immunotherapy.
Journal ArticleDOI
Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies.
Michael Dechant,Wencke Weisner,Sven Berger,Matthias Peipp,Thomas Beyer,Tanja Schneider-Merck,Jeroen J. Lammerts van Bueren,Wim K. Bleeker,Paul W. H. I. Parren,Jan G. J. van de Winkel,Thomas Valerius +10 more
TL;DR: A remarkable synergy for EGFR antibodies is shown, which resulted in potent complement activation via the classic pathway and effective lysis of tumor cells and is exploited to develop novel and more effective treatments for solid cancers.
Journal ArticleDOI
Immature Neutrophils Mediate Tumor Cell Killing via IgA but Not IgG Fc Receptors
Marielle A. Otten,Esther Rudolph,Michael Dechant,Cornelis W. Tuk,Rogier M. Reijmers,Robert H.J. Beelen,Jan G. J. van de Winkel,Jan G. J. van de Winkel,Marjolein van Egmond +8 more
TL;DR: In this paper, the authors examined human and mouse neutrophil-mediated tumor cell lysis via targeting the IgA FcR, FcalphaRI (CD89), in more detail.